Literature DB >> 22379430

Achieving Exemplary Attributes With AccrualNet.

Allison R Baer1, Jane Hajovsky, Robin Zon.   

Abstract

The AccrualNet Web site is a helpful compilation of resources for sites aspiring to improve trial accrual.

Year:  2011        PMID： 22379430      PMCID： PMC3219474          DOI： 10.1200/JOP.2011.000446

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  3 in total

1.  Journal honors Michael Postow, MD, as recipient of the 2013 Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award, supported by JCO.

Authors: 
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

2.  AccrualNet: Addressing Low Accrual Via a Knowledge-Based, Community of Practice Platform.

Authors:  Holly A Massett; Linda K Parreco; Rose Mary Padberg; Ellen S Richmond; Marie E Rienzo; Colleen E Ryan Leonard; Whitney Quesenbery; H William Killiam; Lenora E Johnson; David M Dilts
Journal:  J Oncol Pract       Date:  2011-10-21       Impact factor: 3.840

3.  American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.

Authors:  Robin Zon; Neal J Meropol; Robert B Catalano; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544
  3 in total
  1 in total

1.  The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Authors:  Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol
Journal:  J Oncol Pract       Date:  2013-10-15       Impact factor: 3.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.